Details for New Drug Application (NDA): 217415
✉ Email this page to a colleague
The generic ingredient in DAPTOMYCIN is daptomycin. There are ten drug master file entries for this compound. Twenty-eight suppliers are listed for this compound. Additional details are available on the daptomycin profile page.
Summary for 217415
Tradename: | DAPTOMYCIN |
Applicant: | Xellia Pharms Aps |
Ingredient: | daptomycin |
Patents: | 2 |
Suppliers and Packaging for NDA: 217415
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
DAPTOMYCIN | daptomycin | POWDER;INTRAVENOUS | 217415 | NDA | Xellia Pharmaceuticals USA LLC | 70594-060 | 70594-060-01 | 1 VIAL, SINGLE-USE in 1 CARTON (70594-060-01) / 10 mL in 1 VIAL, SINGLE-USE |
DAPTOMYCIN | daptomycin | POWDER;INTRAVENOUS | 217415 | NDA | Xellia Pharmaceuticals USA LLC | 70594-066 | 70594-066-01 | 1 VIAL, SINGLE-USE in 1 CARTON (70594-066-01) / 7 mL in 1 VIAL, SINGLE-USE |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | POWDER;INTRAVENOUS | Strength | 350MG/VIAL | ||||
Approval Date: | Jan 30, 2023 | TE: | RLD: | Yes | |||||
Patent: | ⤷ Sign Up | Patent Expiration: | Aug 28, 2038 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Patent: | ⤷ Sign Up | Patent Expiration: | Aug 28, 2038 | Product Flag? | Substance Flag? | Delist Request? | |||
Patented Use: | TREATMENT OF THE FOLLOWING INFECTIONS: COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS AND STAPHYLOCOCCUS AUREUS BLOOD STREAM INFECTIONS |
Profile for product number 002
Active Rx/OTC/Discontinued: | RX | Dosage: | POWDER;INTRAVENOUS | Strength | 500MG/VIAL | ||||
Approval Date: | Jan 30, 2023 | TE: | RLD: | Yes | |||||
Patent: | ⤷ Sign Up | Patent Expiration: | Aug 28, 2038 | Product Flag? | Y | Substance Flag? | Delist Request? |
Complete Access Available with Subscription